SIST EN ISO 10993-5:2009

Overview

EN ISO 10993-5:2009 (ISO 10993-5:2009) - "Biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity" - specifies in vitro test methods to assess the cytotoxic potential of medical devices and their materials. The standard defines how cultured mammalian cells are exposed to a device, or to extracts of a device, by direct contact, indirect contact (diffusion), or extract testing, and how biological responses are evaluated using appropriate endpoints.

Key topics

• Scope and purpose: Guidance for selecting and performing in vitro cytotoxicity tests as part of a biological evaluation and risk-management process for medical devices.
• Sample and control preparation: Requirements for preparing devices, extracts and appropriate positive/negative controls before exposure to cell cultures.
• Test methods:
  • Extract tests - exposure of cells to material extracts.
  • Direct-contact tests - placing materials directly onto cell monolayers.
  • Indirect-contact tests - exposure via diffusion through barriers.
• Cell culture components: Selection and preparation of cell lines, culture media and cell stock cultures.
• Test execution: Number of replicates, exposure conditions and procedures to determine cytotoxic effects.
• Endpoints and evaluation: Morphological assessment, measures of cell damage, growth inhibition and metabolic activity; guidance for interpreting results.
• Annexes with example assays: Informative protocols for assays commonly used in cytotoxicity testing (Neutral Red Uptake - NRU, colony formation, MTT, XTT).
• Reporting and assessment: Required elements of the test report and criteria for assessing cytotoxicity outcomes.
• Regulatory alignment: Annexes ZA/ZB mapping the standard to EU Directives (93/42/EEC and 90/385/EEC), supporting conformity assessment.

Applications

• Medical device manufacturers use ISO 10993-5 to:
  • Screen materials and finished devices for cytotoxicity during product development.
  • Support biocompatibility documentation in regulatory submissions and CE marking.
• Contract testing laboratories adopt the standard to provide accredited in vitro cytotoxicity testing services.
• Regulatory reviewers, notified bodies and quality/biocompatibility engineers rely on its methods for safety assessment and comparability studies.

Who should use it

• Biocompatibility specialists, R&D teams, quality assurance, contract testing labs, and regulatory affairs professionals involved in medical device safety evaluation and conformity assessment.

Related standards

• ISO 10993 series (notably Part 1 - evaluation and testing within a risk management process; Part 12 - sample preparation; Part 10/11 for irritation/systemic toxicity)
• National and regional standards/regulations referenced in Annex ZA/ZB for CE marking and regulatory compliance.

Keywords: ISO 10993-5, in vitro cytotoxicity, biological evaluation of medical devices, cytotoxicity tests, MTT, XTT, Neutral Red, medical device testing, ISO 10993.